Eurofins Strengthens Its Non-Invasive Prenatal Testing Technology Portfolio with the Acquisition of a Majority Stake in LifeC...
July 27 2017 - 12:30AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), a global leader in
bio-analytical testing, announces that it has closed the
acquisition of GATC Biotech AG (“GATC”) (see press release
published on June 2nd). This transaction comprises the acquisition
of 62.63% of the shares owned by GATC in LifeCodexx AG
(“LifeCodexx”), one of Europe’s specialists in non-invasive
prenatal testing (NIPT).
As Europe’s first NIPT provider, LifeCodexx, headquartered in
Constance, Germany, has been developing innovative and clinically
validated non-invasive diagnostic tests based on the newest
molecular analytical methods since 2010. With the PrenaTest®,
Europe’s first non-invasive prenatal test for the determination of
the most common chromosomal disorders in unborn children, launched
in 2012, LifeCodexx has been changing prenatal diagnostics
considerably. PrenaTest® is currently available in around 50
countries across Europe, the Middle East and Asia.
Moreover, LifeCodexx successfully transferred its NIPT
technology based on next generation sequencing to several partners
in Germany and Switzerland, and continues to promote technology
transfers to partners in other countries. Following a positive CE
marking, LifeCodexx is currently in the middle of rolling-out its
new, low cost qPCR-based solution for trisomy 21 analysis. The
company generated revenues of about EUR 7m in 2016.
Comment from Dr. Gilles Martin, Eurofins CEO: “Together
with GATC, the acquisition of LifeCodexx will complement Eurofins
technological portfolio in genomic services with unique low cost
qPCR-based NIPT capabilities. We look forward to further developing
Eurofins leading offer in non-invasive prenatal testing, and
providing LifeCodexx access to the complete competencies of the
Eurofins Group and its global distribution network. After the
recent acquisition of Genoma Laboratory Group, this acquisition
should further reinforce Eurofins' footprint in NIPT testing, and
strengthen the Group's technology portfolio in this field.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific SE through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 30,000
staff in 375 laboratories across 41 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific SE are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific SE’s management as of the date of this
release. These forward-looking statements are not guarantees for
future performance, and the forward-looking events discussed in
this release may not occur. Eurofins Scientific SE disclaims any
intent or obligation to update any of these forward-looking
statements and estimates. All statements and estimates are made
based on the information available to the Company’s management as
of the date of publication, but no guarantee can be made as to
their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170726005882/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2024 to May 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From May 2023 to May 2024